<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938314</url>
  </required_header>
  <id_info>
    <org_study_id>NTx®-265-CP-202-IS</org_study_id>
    <nct_id>NCT00938314</nct_id>
  </id_info>
  <brief_title>Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients</brief_title>
  <acronym>REGENESIS-LED</acronym>
  <official_title>A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stem Cell Therapeutics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stem Cell Therapeutics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To assess the neurological outcome in acute ischemic stroke patients treated with
           NTx®-265, when compared with patients given a placebo control.

        -  To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke
           patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS Response &gt;=4 at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead). NIHSS Response &gt;=4 is defined as a &gt;=4 change from baseline at Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS Change From Baseline at Day 30</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) Response &lt;=2 at Day 90</measure>
    <time_frame>Day 90</time_frame>
    <description>The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0 (perfect health without symptoms) to 6 (dead). mRS response &lt;=2 is defined as the mRS score &lt;=2 at Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index at Day 90</measure>
    <time_frame>Day 90</time_frame>
    <description>The Barthel Index measures 10 activities of daily living and mobility. A score of 100 = is best (able to live at home with a degree of independence), 0 is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test (ARAT) Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The ARAT assesses recovery of arm function following stroke through a series of subtests judging ability to grasp, grip, pinch, or move the arm; scores are on a scale; The total maximum (best) score is 57 and the total minimum (worst) score is 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Velocity Test Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The Gait Velocity Test assesses ability to walk as measured by the time (seconds) it takes a patient to walk 10 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Naming Test (BNT) Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The BNT assesses impairment of language ability by asking patients to identify 20 different pictures each time the test is taken. A score of 20 is best, 0 is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Line Cancellation Test Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The Line Cancellation Test detects the loss of awareness of one side of the body. A score of 0.00 (no units) is normal (patient favors neither right nor left side). A score of +1.00 indicates severe unawareness of the left side. A score of -1.00 indicates severe unawareness of the right side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trails A Test Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The Trails A test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 numbers (e.g., 1, 2, 3, 4…)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trails B Test Change From Baseline at Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>The Trails B test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 alpha numeric circles (e.g., 1, A, 2, B, 3, C, 4, D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale at Day 90</measure>
    <time_frame>Day 90</time_frame>
    <description>The Geriatric Depression Scale is commonly used to assess depression in stroke patients of any age by asking 15 yes/no questions, and then scored. A score of 0 - 5 is normal, whereas a score of 6 -15 suggests depression.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>NTx®-265 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTx®-265 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTx®-265 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin (hCG), then epoetin alfa (EPO)</intervention_name>
    <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>NTx®-265 Low Dose</arm_group_label>
    <other_name>Ovidrel</other_name>
    <other_name>Ovitrelle</other_name>
    <other_name>Epogen</other_name>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin (hCG), then epoetin alfa (EPO)</intervention_name>
    <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>NTx®-265 Medium Dose</arm_group_label>
    <other_name>Ovidrel</other_name>
    <other_name>Ovitrelle</other_name>
    <other_name>Epogen</other_name>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin (hCG), then epoetin alfa (EPO)</intervention_name>
    <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>NTx®-265 High Dose</arm_group_label>
    <other_name>Ovidrel</other_name>
    <other_name>Ovitrelle</other_name>
    <other_name>Epogen</other_name>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <other_name>Sodium Chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-85

          -  NIHSS score 8-20

          -  Stroke is ischemic in origin, supratentorial, and radiologically confirmed

          -  Patient is 24-48 hours from time of stroke onset when the first dose of NTx®-265
             therapy is administered

          -  Reasonable expectation of availability to receive the full 9 day NTx®- 265 therapy and
             subsequent follow-up visits

          -  Reasonable expectation that patient will receive standard post-stroke physical,
             occupational, speech, and cognitive therapy as indicated

          -  Female patient is either not of childbearing potential or agrees to use two of the
             effective separate non-hormonal forms of contraception throughout the study

        Exclusion Criteria:

          -  Patients presenting with lacunar, hemorrhagic and/or brain stem stroke

          -  Patients who have received tissue plasminogen activator (tPA)following the index
             stroke

          -  Patients classified as comatose

          -  Women who have tested positive for pregnancy, or are breast-feeding, or are not using
             a birth control

          -  Serum hemoglobin &gt; 16 grams(g)/deciliter (dL)(males) or &gt; 14 g/dL (females); or
             platelet count &gt; 400,000/cubic millimeters(mm3)

          -  Advanced liver, kidney, cardiac, or pulmonary disease

          -  Elevated serum bilirubin,alkaline phosphatase, aspartate aminotransferase (AST) or
             alanine transaminase (ALT),creatinine, or prostate-specific antigen (PSA) levels

          -  Patients with a known history of hypercoagulability

          -  Expected survival &lt; 1 year

          -  Allergy or other contraindication to hCG or EPO

          -  A known diagnosis of cancer in the previous 5 years

          -  Uncontrolled hypertension

          -  Use of either hCG or epoetin alfa within the previous 90 days

          -  Any condition known to elevate hCG

          -  Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS)≥ 2

          -  Any patients not living independently

          -  Any other medical condition or degree of stroke such that, in the investigator's
             opinion, the patient should not be included in the trial

          -  With the exception of the qualifying stroke, any other stroke within the previous 3
             months

          -  Patients who cannot take anti-platelet or anti-coagulant therapy

          -  Pre-existing and active major psychiatric or other chronic neurological disease

          -  Alcohol abuse or have a history of substance abuse or dependency within 12 months
             prior to the study

          -  Currently participating in another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C Cramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of California, Irvine Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Neurosciences, University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Center , University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lalitha Super Specialty Hospitals Pvt.Ltd</name>
      <address>
        <city>Guntur</city>
        <state>Andhra Pradesh</state>
        <zip>522001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Theresa's General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Owaisi Hospital and Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500059</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediciti Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamineni Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DBR &amp; SK Super Speciality Hospital</name>
      <address>
        <city>Tirupati</city>
        <state>Andhra Pradesh</state>
        <zip>517501</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latha Superspecialities Hospital</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suraksha Neuro Centre</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Super Speciality Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.S.S Medical College &amp; Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ananthapuri Hospitals and Research Institute</name>
      <address>
        <city>Thiruvananthapuram</city>
        <state>Kerala</state>
        <zip>695024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vijaya Health Center</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College Hospital</name>
      <address>
        <city>Vellore</city>
        <state>Tamilnadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <results_first_submitted>September 1, 2011</results_first_submitted>
  <results_first_submitted_qc>November 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2011</results_first_posted>
  <last_update_submitted>November 24, 2011</last_update_submitted>
  <last_update_submitted_qc>November 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NTx®-265 Low Dose</title>
          <description>human chorionic gonadotropin (hCG) 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then epoetin alfa (EPO) 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="P2">
          <title>NTx®-265 Medium Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="P3">
          <title>NTx®-265 High Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NTx®-265 Low Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="B2">
          <title>NTx®-265 Medium Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="B3">
          <title>NTx®-265 High Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="B4">
          <title>Saline Placebo</title>
          <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.42" spread="10.49"/>
                    <measurement group_id="B2" value="58.58" spread="13.32"/>
                    <measurement group_id="B3" value="54.83" spread="12.98"/>
                    <measurement group_id="B4" value="61.67" spread="12.38"/>
                    <measurement group_id="B5" value="58.13" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90</title>
        <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90</title>
          <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
          <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="4.22"/>
                    <measurement group_id="O2" value="6.50" spread="4.53"/>
                    <measurement group_id="O3" value="6.08" spread="3.30"/>
                    <measurement group_id="O4" value="7.17" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIHSS Response &gt;=4 at Day 90</title>
        <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead). NIHSS Response &gt;=4 is defined as a &gt;=4 change from baseline at Day 90.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>NIHSS Response &gt;=4 at Day 90</title>
          <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead). NIHSS Response &gt;=4 is defined as a &gt;=4 change from baseline at Day 90.</description>
          <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Response (&lt;4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response (&gt;=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIHSS Change From Baseline at Day 30</title>
        <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
        <time_frame>Baseline and Day 30</time_frame>
        <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>NIHSS Change From Baseline at Day 30</title>
          <description>The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).</description>
          <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="4.53"/>
                    <measurement group_id="O2" value="4.29" spread="3.37"/>
                    <measurement group_id="O3" value="5.00" spread="2.98"/>
                    <measurement group_id="O4" value="5.33" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Scale (mRS) Response &lt;=2 at Day 90</title>
        <description>The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0 (perfect health without symptoms) to 6 (dead). mRS response &lt;=2 is defined as the mRS score &lt;=2 at Day 90.</description>
        <time_frame>Day 90</time_frame>
        <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale (mRS) Response &lt;=2 at Day 90</title>
          <description>The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0 (perfect health without symptoms) to 6 (dead). mRS response &lt;=2 is defined as the mRS score &lt;=2 at Day 90.</description>
          <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>response (mRS &lt;=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (mRS &gt; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barthel Index at Day 90</title>
        <description>The Barthel Index measures 10 activities of daily living and mobility. A score of 100 = is best (able to live at home with a degree of independence), 0 is worst.</description>
        <time_frame>Day 90</time_frame>
        <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Barthel Index at Day 90</title>
          <description>The Barthel Index measures 10 activities of daily living and mobility. A score of 100 = is best (able to live at home with a degree of independence), 0 is worst.</description>
          <population>The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.18" spread="29.62"/>
                    <measurement group_id="O2" value="80.17" spread="22.04"/>
                    <measurement group_id="O3" value="85.25" spread="20.28"/>
                    <measurement group_id="O4" value="90.89" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Action Research Arm Test (ARAT) Change From Baseline at Day 90</title>
        <description>The ARAT assesses recovery of arm function following stroke through a series of subtests judging ability to grasp, grip, pinch, or move the arm; scores are on a scale; The total maximum (best) score is 57 and the total minimum (worst) score is 0.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Action Research Arm Test (ARAT) Change From Baseline at Day 90</title>
          <description>The ARAT assesses recovery of arm function following stroke through a series of subtests judging ability to grasp, grip, pinch, or move the arm; scores are on a scale; The total maximum (best) score is 57 and the total minimum (worst) score is 0.</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.67" spread="13.37"/>
                    <measurement group_id="O2" value="33.50" spread="26.12"/>
                    <measurement group_id="O3" value="30.33" spread="16.80"/>
                    <measurement group_id="O4" value="23.75" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gait Velocity Test Change From Baseline at Day 90</title>
        <description>The Gait Velocity Test assesses ability to walk as measured by the time (seconds) it takes a patient to walk 10 meters.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Velocity Test Change From Baseline at Day 90</title>
          <description>The Gait Velocity Test assesses ability to walk as measured by the time (seconds) it takes a patient to walk 10 meters.</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.75" spread="41.60"/>
                    <measurement group_id="O2" value="-50.33" spread="48.95"/>
                    <measurement group_id="O3" value="-6.40" spread="7.37"/>
                    <measurement group_id="O4" value="-53.80" spread="54.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Boston Naming Test (BNT) Change From Baseline at Day 90</title>
        <description>The BNT assesses impairment of language ability by asking patients to identify 20 different pictures each time the test is taken. A score of 20 is best, 0 is worst.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Boston Naming Test (BNT) Change From Baseline at Day 90</title>
          <description>The BNT assesses impairment of language ability by asking patients to identify 20 different pictures each time the test is taken. A score of 20 is best, 0 is worst.</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="3.10"/>
                    <measurement group_id="O2" value="4.17" spread="4.11"/>
                    <measurement group_id="O3" value="0.20" spread="2.74"/>
                    <measurement group_id="O4" value="3.69" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Line Cancellation Test Change From Baseline at Day 90</title>
        <description>The Line Cancellation Test detects the loss of awareness of one side of the body. A score of 0.00 (no units) is normal (patient favors neither right nor left side). A score of +1.00 indicates severe unawareness of the left side. A score of -1.00 indicates severe unawareness of the right side.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Line Cancellation Test Change From Baseline at Day 90</title>
          <description>The Line Cancellation Test detects the loss of awareness of one side of the body. A score of 0.00 (no units) is normal (patient favors neither right nor left side). A score of +1.00 indicates severe unawareness of the left side. A score of -1.00 indicates severe unawareness of the right side.</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.03"/>
                    <measurement group_id="O2" value="-0.07" spread="0.11"/>
                    <measurement group_id="O3" value="-0.04" spread="0.10"/>
                    <measurement group_id="O4" value="-0.00" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trails A Test Change From Baseline at Day 90</title>
        <description>The Trails A test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 numbers (e.g., 1, 2, 3, 4…)</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Trails A Test Change From Baseline at Day 90</title>
          <description>The Trails A test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 numbers (e.g., 1, 2, 3, 4…)</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.33" spread="22.20"/>
                    <measurement group_id="O2" value="-21.89" spread="22.10"/>
                    <measurement group_id="O3" value="-13.29" spread="21.91"/>
                    <measurement group_id="O4" value="-23.44" spread="25.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trails B Test Change From Baseline at Day 90</title>
        <description>The Trails B test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 alpha numeric circles (e.g., 1, A, 2, B, 3, C, 4, D)</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Trails B Test Change From Baseline at Day 90</title>
          <description>The Trails B test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 alpha numeric circles (e.g., 1, A, 2, B, 3, C, 4, D)</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.33" spread="51.60"/>
                    <measurement group_id="O2" value="-41.33" spread="62.89"/>
                    <measurement group_id="O3" value="-55.14" spread="59.92"/>
                    <measurement group_id="O4" value="-22.78" spread="71.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geriatric Depression Scale at Day 90</title>
        <description>The Geriatric Depression Scale is commonly used to assess depression in stroke patients of any age by asking 15 yes/no questions, and then scored. A score of 0 – 5 is normal, whereas a score of 6 -15 suggests depression.</description>
        <time_frame>Day 90</time_frame>
        <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>NTx®-265 Low Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O2">
            <title>NTx®-265 Medium Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O3">
            <title>NTx®-265 High Dose</title>
            <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
          </group>
          <group group_id="O4">
            <title>Saline Placebo</title>
            <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Geriatric Depression Scale at Day 90</title>
          <description>The Geriatric Depression Scale is commonly used to assess depression in stroke patients of any age by asking 15 yes/no questions, and then scored. A score of 0 – 5 is normal, whereas a score of 6 -15 suggests depression.</description>
          <population>Not all patients enrolled in the group completed this outcome measure.
The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="4.24"/>
                    <measurement group_id="O2" value="3.88" spread="3.08"/>
                    <measurement group_id="O3" value="3.56" spread="2.77"/>
                    <measurement group_id="O4" value="4.74" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured from the time of first dose to Day 30. Serious adverse events were captured from the time of first dose to Day 90.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NTx®-265 Low Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="E2">
          <title>NTx®-265 Medium Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="E3">
          <title>NTx®-265 High Dose</title>
          <description>hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
        </group>
        <group group_id="E4">
          <title>Saline Placebo</title>
          <description>saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Vascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Transformation Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated after 96 of a planned 128 patients were enrolled, thus limiting opportunities to demonstrate a clear statistical benefit of active therapy compared to placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Stem Cell Therapeutics Corp.</organization>
      <phone>403.245.5495 ext 226</phone>
      <email>adavidoff@stemcellthera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

